- Alkem Laboratories reported a 21.7% decline in Q1 net profit, totaling ₹520 crore compared to ₹664 crore YoY.
- Bharat Dynamics saw its Q1 net profit jump to ₹119 crore, a significant increase from ₹18.3 crore YoY.
- Natco Pharma reported an 84% year-on-year decline in standalone PAT, amounting to ₹74.6 crore.
- 3M India experienced a 31.1% increase in PAT, reaching ₹233.07 crore in Q1.
- Ashok Leyland reported a standalone PAT of ₹609.11 crore, which is up 2.5% year-on-year but down 56.6% sequentially.
- Max Healthcare shares fell 2% after reporting a PAT of ₹357 crore.
- Page Industries reported a 4% dip in PAT, totaling ₹192.80 crore in Q1.
- Alkem Labs reported a 13.3% year-on-year decline in Q1, with profits at ₹569.98 crore compared to ₹656.16 crore in the previous year.
- Bharat Dynamics reported a standalone PAT of ₹118.79 crore in Q1FY27, up from ₹18.35 crore in Q1FY26.
- Ashok Leyland reported a 56.6% decline in PAT sequentially from ₹1404.72 crore in the previous quarter.
Bharat Dynamics reported a net profit of ₹119 crore for Q1FY27, a substantial increase from ₹18.3 crore in the same quarter last year. The company's revenue surged to ₹572 crore, compared to ₹248 crore a year ago, with an EBITDA of ₹82.8 crore compared to a loss of ₹45.3 crore previously. The EBITDA margin improved to 14.5%.29
In contrast, Alkem Laboratories experienced a 21.7% drop in net profit, falling to ₹520 crore from ₹664 crore year-on-year. Despite this decline, the company reported a revenue increase of 10.9% to ₹3,740 crore, with an EBITDA rise of 3.7% to ₹766 crore. The EBITDA margin decreased to 20.5% from 21.9% in the previous year, and tax expenses rose significantly to ₹251 crore from ₹103 crore.1

These results highlight the mixed performance of Indian companies in the current earnings season, with Bharat Dynamics showcasing strong growth while Alkem Laboratories grapples with profitability challenges amidst rising costs and competitive pressures.
“Natco Pharma's PAT plunged 84% to ₹74.6 crore, with shares falling over 6% to ₹893 on the NSE. Ashok Leyland's PAT rose 2.5% y-o-y but dropped 56.6% sequentially, while its CEO cited robust demand and cost-saving initiatives.”







